版本:
中国

BRIEF-Kempharm receives clearance from FDA to initiate clinical program for KP415

Oct 11 Kempharm Inc :

* Kempharm receives clearance from FDA to initiate clinical program for KP415, an investigational prodrug of D-threo-methylphenidate for the treatment of ADHD

* Kempharm Inc says expects to commence and complete proof of concept human trials prior to end of 2016

* Kempharm Inc says kempharm anticipates submitting a new drug application (NDA) submission for kp415 as early as 2018

* Kempharm Inc - additional human clinical trials initiating during first half of 2017 Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐